ATE274919T1 - Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung - Google Patents

Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung

Info

Publication number
ATE274919T1
ATE274919T1 AT98950200T AT98950200T ATE274919T1 AT E274919 T1 ATE274919 T1 AT E274919T1 AT 98950200 T AT98950200 T AT 98950200T AT 98950200 T AT98950200 T AT 98950200T AT E274919 T1 ATE274919 T1 AT E274919T1
Authority
AT
Austria
Prior art keywords
vaccine composition
oral administration
solid dispersing
adjuvant
mucosal tissue
Prior art date
Application number
AT98950200T
Other languages
English (en)
Inventor
Harry Seager
Original Assignee
Scherer Corp R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Corp R P filed Critical Scherer Corp R P
Application granted granted Critical
Publication of ATE274919T1 publication Critical patent/ATE274919T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
AT98950200T 1997-10-27 1998-10-27 Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung ATE274919T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9722682.3A GB9722682D0 (en) 1997-10-27 1997-10-27 Pharmaceutical products
PCT/GB1998/003209 WO1999021579A1 (en) 1997-10-27 1998-10-27 Solid dispersing vaccine composition for oral delivery

Publications (1)

Publication Number Publication Date
ATE274919T1 true ATE274919T1 (de) 2004-09-15

Family

ID=10821162

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950200T ATE274919T1 (de) 1997-10-27 1998-10-27 Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung

Country Status (10)

Country Link
EP (1) EP1024824B1 (de)
JP (1) JP2001521007A (de)
AT (1) ATE274919T1 (de)
AU (1) AU9635998A (de)
DE (1) DE69826019T2 (de)
DK (1) DK1024824T3 (de)
ES (1) ES2227885T3 (de)
GB (1) GB9722682D0 (de)
PT (1) PT1024824E (de)
WO (1) WO1999021579A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
PT1212045T (pt) 1999-08-24 2016-11-22 Abic Biological Laboratories Ltd Composição de vacina e método de utilização da mesma
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
DE10125731A1 (de) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Darreichungsform von immunologischen Wirkstoffen
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
AU2004216559B2 (en) 2003-02-28 2010-05-27 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
EP1709975A1 (de) * 2003-07-10 2006-10-11 Kyowa Hakko Kogyo Co., Ltd. Tablette und herstellungsverfahren dafür
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
CN1878563A (zh) 2003-11-10 2006-12-13 西摩·H·费恩 包含低剂量去氨加压素的药物组合物
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
DK2187926T3 (da) 2007-09-11 2012-04-02 Univ Koebenhavn Forebyggelse af diabetes ved administration af gliadin
EP2163239A1 (de) * 2008-05-27 2010-03-17 Qiagen GmbH Produkte, die Biopartikel enthalten, Verfahren zu ihrer Herstellung
EP2453916A4 (de) * 2009-07-17 2013-06-05 Univ Oklahoma State Supralinguale impfstoffe und applikatoren
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US9956169B2 (en) * 2010-10-08 2018-05-01 R.P. Scherer Technologies, Llc Oral vaccine fast-dissolving dosage form using starch
EP2952200A1 (de) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergen zur vorbeugenden Behandlung von Allergien
TWI745278B (zh) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
JPH08508247A (ja) * 1993-03-11 1996-09-03 セクレテック，インク． 粘膜表面への免疫原の輸送における重合的粘膜付着体
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery

Also Published As

Publication number Publication date
PT1024824E (pt) 2004-11-30
DE69826019T2 (de) 2005-09-15
GB9722682D0 (en) 1997-12-24
WO1999021579A1 (en) 1999-05-06
ES2227885T3 (es) 2005-04-01
DE69826019D1 (de) 2004-10-07
DK1024824T3 (da) 2004-09-20
AU9635998A (en) 1999-05-17
EP1024824B1 (de) 2004-09-01
JP2001521007A (ja) 2001-11-06
EP1024824A1 (de) 2000-08-09

Similar Documents

Publication Publication Date Title
DE69826019D1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
IL145982A0 (en) Vaccines
LU91326I2 (fr) Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
GB0025577D0 (en) Vaccine
DZ2462A1 (fr) Vaccin antigrippal.
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ATE395916T1 (de) Orale methylphenidat-formulierungen mit kontrollierter/veränderter freisetzung
BR9910643A (pt) Processos e produtos para a indução de imunidadede mucosa
DK1259259T3 (da) Mucosal adjuvansformulering
EP1471936A4 (de) Hiv-vakzine und anwendungsverfahren
NO972219D0 (no) Immunogenpreparater
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
DE69510858T2 (de) Mukosale Verabreichung von Pneumokokken-Antigenen
BR9815404A (pt) Composição adjuvante para estimular uma eficiente resposta imunológica a uma substância antigênica, vacina para administração a um animal, processo para estimular uma resposta imunológica eficaz em um animal a uma substância antigênica, e, uso da composição adjuvante.
HUP0400495A3 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
CU23077A1 (es) Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
MY127452A (en) Vaccines.
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней
UA23884A (uk) Спосіб підвищення імунітету у сільськогосподарськи х птиць при вакцинації її живими вірус-вакцинами

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1024824

Country of ref document: EP